Hematological Cancers - A Therapeutic & Competitive Insight

Introduction

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma. The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide through this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
As well, leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis’ Gleevec (imatinib mesylate) for chronic myeloid leukemia, which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise of 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.

Research and analysis highlights

BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. The most actively discussed and interesting drugs were selected and presented. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. In this report, BioSeeker provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. We present both an overview and a detailed description on the progress of 100 key drugs in Phase II and III development, together with general descriptions on drugs and targets. Among these drugs BioSeeker clearly sees a substantial progress for some while others have failed. There will be a more intense competition in several of the sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

• Thorough examination of status and impact of several novel drugs in development
• Discussion of the challenges in current and future treatment strategies
• Anticancer pipeline of most companies in the field

Key reasons to read this report

• Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in R&D, and the results of clinical trials to date.
• Gain insight into the current challenges and commercial opportunities associated with therapy for the hematological cancers.
• More than 190 high quality references.

Some of the drugs included in this analysis

AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.

Some of the companies included in this analysis

Abgenix (Amgen), Accentia BioPharmaceuticals, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cell Therapeutics, Cephalon, Chiron (now Novartis) Corporation, Corixa (GSK), Cyclacel Group (Cyclacel), Eli Lilly, Exelixis, Favrille, Genentech, Genitope, Genmab, Genta, GlaxoSmithKline, Immunomedics, Inex Pharmaceuticals, Johnson & Johnson, Millennium Pharmaceuticals, Novartis, Pharmacyclics, Protein Design Labs, Roche, Sanofi-Aventis, Schering-Plough, Seattle Genetics, SuperGen, Vion Pharmaceuticals, Wyeth etc.